Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
United Nations Secretary-General António Guterres has issued the strong warning about the growing dangers of…
The State government of Rajasthan has constituted a five-member committee to prepare a draft law…
India's first Made In India C295 transport aircraft is set to be delivered to the…
On 23rd to 24th June, 2026 in Bengaluru India hosting the BRICS Heads of Space…
India has secured the 13th position in the QS World Future Skills Index of 2027…
The latest International Monetary Fund (IMF) World Economic Outlook Report which released in the April…